Meriggi F, Forni E
Clinica Chirurgica Generale, Università degli Studi di Pavia.
G Chir. 1996 Jun-Jul;17(6-7):370-8.
A posthepatitic cirrhotic patient may undergo elective or urgent abdominal operation for an extra-hepatic or hepatic disease. According to the high postoperative morbidity (61%), surgery is indicated only for symptomatic or complicated cholelithiasis. A surgical procedure for refractory ascites has been devised to create a permanent peritoneo-venous shunt by a one way pressure-sensitive valve (Leveen). The procedure is simple and brings a long lasting relief with recovery in strength and nutrition and improved kidney function. Sclerotherapy is widely used to treat acute variceal bleeding while repeated sclerotherapy is used in the long-term management to eradicate varices. When indicated, liver transplantation is the best treatment to prevent variceal bleeding recurrence. Also portosystemic shunts effectively prevent recurrent variceal bleeding. They are, however, major operations with an important morbidity and mortality, particularly in poor risk patients. The most advocated shunts today are the Warren distal splenorenal shunt and the Sarfeh portacaval shunt using a small diameter prosthetic H-graft. The transjugular intrahepatic portosystemic stent-shunt (TIPSS) is a new treatment for portal hypertension and its complications. From a haemodynamic point of view it allows balanced hepatic perfusion. Postoperative mortality is rare; further bleeding and encephalopathy are reasonably acceptable. The most relevant complications concern dislocation of the prosthesis, stenosis and thrombosis of the shunt, which can be corrected by non-invasive dilatation. Encephalopathy is the main complication of surgical portosystemic shunts. It is usually controlled by protein diet restriction, and administration of lactulose or oral antibiotics. In severe forms the patients may be treated by an oesophageal transection with oesophagogastric devascularization, and by a postoperative suppression of the portosystemic shunt using external maneuvers. Posthepatitic liver cirrhosis is frequently complicated by the onset of an hepatocellular carcinoma. Early detection (aFP, DCP, Echography) and curative resection are the best ways to improve long term prognosis. Segmentectomy achieves a good balance between liver function preservation and radical exeresis for tumours less than 5 cm in diameter. Liver transplantation may be considered for the treatment of long-staging cirrhotic patients in whom hepatocarcinoma development has been recognized at an early presymptomatic stage. Hepatic arterial chemoembolization (gelfoam, lipiodol, mitomycin C or doxorubicin) may improve the survival of patients with unresectable malignant disease of the liver. A marked reduction in liver size may occur in the weeks following an effective chemoembolization with objective (CT scan) and subjective improvement (amelioration of specific symptoms). Liver chemoembolization is absolutely contraindicated in the presence of jaundice disordered liver function (Child C) or complete portal venous obstruction. In the last years, the number of patients treated by liver transplantation has greatly increased. Surgical technique, postoperative management, and immunosuppressive therapy account for the dramatic improvement of the results. However, indications for selection of patients and the timing for liver transplantation are still not well defined.
肝炎后肝硬化患者可能因肝外或肝脏疾病接受择期或急诊腹部手术。鉴于术后高发病率(61%),手术仅适用于有症状的或复杂的胆石症。已设计出一种用于难治性腹水的外科手术,通过单向压力敏感瓣膜(Leveen)建立永久性腹膜 - 静脉分流。该手术简单,能带来持久缓解,使体力和营养恢复,并改善肾功能。硬化疗法广泛用于治疗急性静脉曲张出血,而反复硬化疗法用于长期管理以根除静脉曲张。在有指征时,肝移植是预防静脉曲张出血复发的最佳治疗方法。此外,门体分流术可有效预防复发性静脉曲张出血。然而,它们是大手术,有重要的发病率和死亡率,尤其在高危患者中。如今最受推崇的分流术是Warren远端脾肾分流术和使用小直径人工H型移植物的Sarfeh门腔分流术。经颈静脉肝内门体支架分流术(TIPSS)是治疗门静脉高压及其并发症的一种新方法。从血流动力学角度看,它能实现肝脏灌注平衡。术后死亡率罕见;进一步出血和肝性脑病在合理范围内可接受。最相关的并发症涉及假体脱位、分流狭窄和血栓形成,可通过非侵入性扩张纠正。肝性脑病是外科门体分流术的主要并发症。通常通过限制蛋白质饮食以及给予乳果糖或口服抗生素来控制。在严重形式下,患者可通过食管横断术加食管胃去血管化治疗,并通过外部操作在术后抑制门体分流。肝炎后肝硬化常并发肝细胞癌。早期检测(甲胎蛋白、异常凝血酶原、超声检查)和根治性切除是改善长期预后的最佳方法。对于直径小于5cm的肿瘤,肝段切除术在肝功能保留和根治性切除之间实现了良好平衡。对于已在症状前期早期被诊断出肝癌的晚期肝硬化患者,可考虑肝移植治疗。肝动脉化疗栓塞术(明胶海绵、碘油、丝裂霉素C或阿霉素)可提高不可切除的肝脏恶性疾病患者的生存率。有效的化疗栓塞术后数周肝脏大小可能会明显缩小,有客观(CT扫描)和主观改善(特定症状改善)。肝功能紊乱(Child C级)伴有黄疸或完全门静脉阻塞时,绝对禁忌肝化疗栓塞术。近年来接受肝移植治疗的患者数量大幅增加。手术技术、术后管理和免疫抑制治疗使结果有了显著改善。然而,患者选择的指征和肝移植的时机仍未明确界定。